Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Raltegravir Potassium»

Raltegravir Potassium

Pronunciation: (ral-TEG-ra-vir poe-TAS-ee-um)Class: Antiretroviral, Integrase inhibitor

Trade Names:Isentress- Tablets 400 mg


Raltegravir is an HIV-1 antiviral agent that blocks the enzyme HIV-1 integrase that is needed for viral replication.



T max is approximately 3 h postdose. AUC and C max increase dose proportionally. Steady state is reached in approximately 2 days. Administration with a high-fat meal increases the AUC and C max by approximately 2-fold. Administration with a low-fat meal decreased the AUC and C max 46% and 52%, respectively.


Human plasma protein binding is approximately 83%.


Raltegravir is metabolized to raltegravir-glucuronide by the enzyme UGT1A1.


The half-life is approximately 9 h. Approximately 51% and 32% of an administered dose is excreted in feces and urine, respectively.

Special Populations

Renal Function Impairment

No clinically important pharmacokinetic differences were observed between subjects with severe renal impairment and healthy subjects. Because the extent to which raltegravir is dialyzable is unknown, avoid dosing before dialysis.

Hepatic Function Impairment

No clinically important pharmacokinetic differences were observed between subjects with moderate hepatic impairment and healthy subjects. Effect of severe hepatic impairment has not been studied.

Age, gender, race

No dosage adjustments are needed.

Indications and Usage

Treatment of HIV-1 infection in combination with other antiretroviral agents.


None well documented.

Dosage and Administration


PO 400 mg twice daily.

Coadministration of RifampinAdults

PO 800 mg twice daily.

General Advice

  • May be given with or without food.


Store at 59° to 86°F.

Drug Interactions

Drugs that are strong inducers of UGT1A1 (eg, rifampin)

Raltegravir plasma levels may be reduced. The recommended dosage of raltegravir is 800 mg twice daily during coadministration with rifampin. Coadminister with caution.

Drugs that inhibit UGT1A1 (eg, atazanavir, atazanavir/ritonavir)

Raltegravir plasma levels may be increased; however, dosage adjustments are not needed with coadministration of atazanavir/ritonavir. Monitor the response of the patient.

Efavirenz, etravirine

Raltegravir plasma concentrations may be reduced. The clinical importance has not been assessed. Monitor the response of the patient.


Raltegravir plasma concentrations may be increased because of increased solubility at higher pH. Dosage adjustments do not appear to be necessary. Monitor the response of the patient.


Raltegravir plasma concentrations may be reduced. No dosage adjustment is recommended. Monitor the response of the patient.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Insomnia (4%); abnormal dreams, dizziness (less than 2%); asthenia; fatigue; headache; anxiety, depression, paranoia, suicidal ideation and behavior (postmarketing).


Rash, Stevens-Johnson syndrome (postmarketing).


Abdominal pain, gastritis (less than 2%); nausea.


Genital herpes, renal failure (less than 2%).


Hepatitis (less than 2%).


Hypersensitivity (less than 2%).

Lab Tests

Decreased hemoglobin, neutrophils, triglycerides, and platelets; increased serum alkaline phosphatase, ALT, AST, bilirubin, creatine kinase, fasting glucose, HDL cholesterol , lipase, LDL cholesterol, total cholesterol, and pancreatic amylase.


Herpes zoster (less than 2%).



Monitor CD4+ cell count and HIV-1 RNA load.


Category C .


Undetermined; however, HIV-infected mothers should not breast-feed.


Safety and effectiveness not established.


Select dose with caution because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.

Hepatic Function

Effect of severe hepatic impairment has not been studied.

Immune reconstitution syndrome

During initial phase of treatment, patients may develop an inflammatory response to indolent or residual opportunistic infections (eg, Mycobacterium avium complex), which may require further evaluation and treatment.



No information is available.

Patient Information

  • Advise patient to read the patient information leaflet before using product the first time and with each refill.
  • Inform patient that this medication is not a cure for HIV infection or AIDS.
  • Emphasize to patient, family, and significant others that this medication does not reduce the risk of transmitting HIV to others through sexual contact or blood contamination.
  • Advise patients to take this medication exactly as prescribed, with or without food.
  • Warn patients not to alter dose or discontinue medication without consulting health care provider.
  • Explain that the long-term effects of this medication are not known.
  • Inform patients to report symptoms of unexplained muscle pain, tenderness, or weakness to health care provider.
  • Advise breast-feeding women not to breast-feed while taking this medicine.

Copyright © 2009 Wolters Kluwer Health.